Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Capricor

US stocks: Capricor shares 77% soar as potential FDA lifeline revives Duchenne drug hopes

Capricor Therapeutics shares surged significantly after the FDA agreed to review new drug data. The company had faced setbacks last month regarding its experimental Duchenne muscular dystrophy treatment. New 24-month data will focus on improving upper limb muscle function for the drug. Analysts view the FDA's willingness to review this…

The Economic Times

Benzinga Bulls And Bears: Amazon, Microsoft, SpaceX

Benzinga Bulls And Bears: Amazon, Microsoft, SpaceX

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.

Duchenne Families Face a Three-Week Wait After FDA Advisers Rejected the Heart Therapy Evidence

Duchenne Families Face a Three-Week Wait After FDA Advisers Rejected the Heart Therapy Evidence

FDA advisers voted 9-3 that evidence for dermaicell falls short for Duchenne cardiomyopathy. The FDA decides by August 22. What families should know.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Capricor Therapeutics Q1 Earnings Call Highlights

Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself amid a legal dispute with distribution partner NS Pharma and parent company Nippon Shinyaku. On t

Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say

Capricor Therapeutics, Inc. (NASDAQ:CAPR) stock soared on Wednesday after the company announced positive topline data from the Phase 3 HOPE-3 trial for its lead cell therapy candidate, deramiocel.

Capricor Therapeutics (CAPR) Stock Is Sliding Today: Should Retail Investors Be Worried?

Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading lower Monday morning after the company reported new data from its exosome-based drug delivery platform. Here’s what investors need to know.

Why Capricor Therapeutics Stock Is Surging Today

Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are up Thursday after the company announced progress regarding one of its rare disease therapeutics. The biotech company’s stock jumped 18% immediately following the news.

inkl

Read news from The Economist, FT, and more,
with one subscription

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Friday.

Capricor Shares Fall After Topline Results From Mid-Stage COVID-19 Trial

Capricor Shares Fall After Topline Results From Mid-Stage COVID-19 Trial

Capricor Therapeutics Inc (NASDAQ: CAPR) announced topline data from its Phase 2 INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 for hospitalized COVID-19 patients.

Capricor Stops Work On Exosome-mRNA Based COVID-19 Vaccine Candidate

Capricor Stops Work On Exosome-mRNA Based COVID-19 Vaccine Candidate

In its Q4 FY21 earnings press release, Capricor Therapeutics Inc (NASDAQ:

Capricor Therapeutics, Nippon Shinyaku Ink US Pact For Duchenne Muscular Dystrophy Candidate

Capricor Therapeutics, Nippon Shinyaku Ink US Pact For Duchenne Muscular Dystrophy Candidate

Capricor Therapeutics Inc (NASDAQ: CAPR) has partnered with Nippon Shinyaku Co Ltd for the

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Amazon.com Inc.

the Bureau of Prisons

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

408,023 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play